上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
TWS119 纯度: ≥98.0%
TWS119 是一种 GSK-3β 特异性抑制剂,IC50 值为 30 nM,同时可激活 wnt/β-catenin 信号通路。
TWS119 Chemical Structure
CAS No. : 601514-19-6
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO | ¥972 | In-stock | |
10 mg | ¥884 | In-stock | |
50 mg | ¥3464 | In-stock | |
100 mg | ¥5580 | In-stock | |
200 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
TWS119 相关产品
•相关化合物库:
- Bioactive Compound Library Plus
- Kinase Inhibitor Library
- PI3K/Akt/mTOR Compound Library
- Stem Cell Signaling Compound Library
- Wnt/Hedgehog/Notch Compound Library
- Anti-Cancer Compound Library
- Autophagy Compound Library
- Anti-Aging Compound Library
- Reprogramming Compound Library
- Oxygen Sensing Compound Library
- Glycolysis Compound Library
- Cytoskeleton Compound Library
- Anti-Alzheimer’s Disease Compound Library
- Anti-Pancreatic Cancer Compound Library
- Anti-Cancer Metabolism Compound Library
- Neurodegenerative Disease-related Compound Library
- Glucose Metabolism Compound Library
生物活性 |
TWS119 is a specific inhibitor of GSK-3β, with an IC50 of 30 nM, and activates the wnt/β-catenin pathway. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1] |
|
||||||||||||||||
体外研究 (In Vitro) |
TWS119 induces neuronal differentiation in P19 EC cells and primary mouse ESCs. TWS119 binds to GSK-3β with KD of 126 nM, and modulates the activity of the complex, triggering downstream transcriptional events that lead the neuronal induction[1]. TWS119 (< 4 μM) significantly enhances the proliferation and survival of γδT cells via activation of the mammalian target of rapamycin (mTOR) pathway, upregulation of the expression of anti-apoptotic protein Bcl-2 and inhibition of cleaved caspase-3. TWS119 (0-8 μM) induces the generation of CD62L+γδT or CCR5+γδT cell phenotypes. TWS119 (0.5, 1.0 and 2 μM) increases the expression level of granzyme B in a dose-dependent manner. TWS119 also enhances the cytolytic activity of γδT cells against tumour cells in vitro[3]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
体内研究 (In Vivo) |
TWS119 (30 mg/kg, i.p.) improves the neurologic function and decreases neurologic deficit dcore in rtPA-treated MCAO rats. TWS119 effectively relieves cerebral edema, and reduces cerebral infarction in rats treated with rtPA. TWS119 also effectively decreases blood-brain barrier permeability in rtPA-Treated MCAO Rats and attenuates rtPA-induced hemorrhage in ischemic brain tissue. Futhermore, TWS119 activates the Wnt/β-Catenin signaling pathway and increases the expression of Claudin-3 and ZO-1[2]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
分子量 |
318.33 |
||||||||||||||||
Formula |
C18H14N4O2 |
||||||||||||||||
CAS 号 |
601514-19-6 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : ≥ 50 mg/mL (157.07 mM) H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble) * “≥” means soluble, but saturation unknown. 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
Cell Assay [3] |
PBMCs are cultured with pamidronate disodium for 8 days and then cells are labelled with or without 1.5 μM carboxyfluorescein succinimidyl ester (CFSE) and CFSE-labelled cells are then seeded in 6-well plates (2.5 × 106 cells/well) followed by treatment with various concentrations of TWS119 for 72 h. The total number of cultured cells is evaluated using an automated cell counter and the γδT cell proliferation is examined by flow cytometry[3]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
---|---|
Animal Administration [2] |
All rats are randomly divided into four groups as follows: Sham group-rats undego the same surgical procedure, but the filament is not inserted and they receive 1 mL of dimethyl sulfoxide (1 % DMSO in saline); Vehicle group-rats undergo MCAO and receive 1 mL of DMSO; rtPA group-rats underwent MCAO and receive rtPA (10 mg/kg, Actilyse®) at 4 h after MCAO; and rtPA+TWS119 group-rats undergo MCAO and receive intraperitoneal TWS119 (30 mg/kg, dissolved in 1 mL 1 % DMSO) immediately after rtPA injection at 4 h after MCAO[2]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务